Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment

Bisphosphonates in the management of postmenopausal osteoporosis – optimizing efficacy in clinical practice

(2016) Oliver Bock   Clinical Interventions in Aging

Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study

(2010) H. Eidtmann et al.   ANNALS OF ONCOLOGY

Assessment of fracture risk in women with breast cancer using current vs emerging guidelines

(2010) P Hadji et al.   BRITISH JOURNAL OF CANCER

The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer

(2010) R E Coleman et al.   BRITISH JOURNAL OF CANCER

Bisphosphonates for osteoporosis treatment are associated with reduced breast cancer risk

(2010) P A Newcomb et al.   BRITISH JOURNAL OF CANCER

Prevention of Aromatase Inhibitor–Induced Bone Loss Using Risedronate: The SABRE Trial

(2010) Catherine Van Poznak et al.   JOURNAL OF CLINICAL ONCOLOGY

Oral Bisphosphonate Use and Breast Cancer Incidence in Postmenopausal Women

(2010) Rowan T. Chlebowski et al.   JOURNAL OF CLINICAL ONCOLOGY

Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study

(2010) Alison T. Stopeck et al.   JOURNAL OF CLINICAL ONCOLOGY

First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial

(2010) Gareth J Morgan et al.   LANCET

Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial

(2010) Rebecca Aft et al.   LANCET ONCOLOGY

Cost of fractures commonly associated with osteoporosis in a managed-care population

(2010) L. Christensen et al.   JOURNAL OF MEDICAL ECONOMICS

Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer

(2009) V. Ziller et al.   ANNALS OF ONCOLOGY

Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial

(2009) M. Rabaglio et al.   ANNALS OF ONCOLOGY

Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009

(2009) A. Goldhirsch et al.   ANNALS OF ONCOLOGY

Direct healthcare costs of hip, vertebral, and non-hip, non-vertebral fractures

(2009) Nianwen Shi et al.   BONE

Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC

(2009) Stephanie L. Hines et al.   BREAST CANCER RESEARCH AND TREATMENT

Improving compliance and persistence to adjuvant tamoxifen and aromatase inhibitor therapy

(2009) Peyman Hadji   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Mortality Risk Associated With Low-Trauma Osteoporotic Fracture and Subsequent Fracture in Men and Women

(2009) Dana Bliuc   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Analysis of Factors Influencing Outcome in Patients With In-Transit Malignant Melanoma Undergoing Isolated Limb Perfusion Using Modern Treatment Parameters

(2009) H. Richard Alexander et al.   JOURNAL OF CLINICAL ONCOLOGY

Meta-Analysis of Breast Cancer Outcomes in Adjuvant Trials of Aromatase Inhibitors Versus Tamoxifen

(2009) Mitch Dowsett et al.   JOURNAL OF CLINICAL ONCOLOGY

Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast Cancer

(2009) Michael Gnant et al.   NEW ENGLAND JOURNAL OF MEDICINE

Adverse bone effects during pharmacological breast cancer therapy

(2008) Nina H. Bjarnason et al.   ACTA ONCOLOGICA

Practical guidance for the management of aromatase inhibitor-associated bone loss

(2008) P. Hadji et al.   ANNALS OF ONCOLOGY

Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow--a long-term follow-up

(2008) I. J. Diel et al.   ANNALS OF ONCOLOGY

Effect of Tamoxifen and Aromatase Inhibitors on the Risk of Fractures in Women with Breast Cancer

(2008) Peter Vestergaard et al.   CALCIFIED TISSUE INTERNATIONAL

Prevention of Anastrozole-Induced Bone Loss with Monthly Oral Ibandronate during Adjuvant Aromatase Inhibitor Therapy for Breast Cancer

(2008) J. E. Lester et al.   CLINICAL CANCER RESEARCH

Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis

(2008) Peyman Hadji   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Zoledronsäure bei persistierenden isolierten Tumorzellen im Knochenmark bei Mammakarzinom

(2008) B Rack et al.   DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT

Randomized Trial of Denosumab in Patients Receiving Adjuvant Aromatase Inhibitors for Nonmetastatic Breast Cancer

(2008) Georgiana K. Ellis et al.   JOURNAL OF CLINICAL ONCOLOGY

Risedronate Prevents Bone Loss in Breast Cancer Survivors: A 2-Year, Randomized, Double-Blind, Placebo-Controlled Clinical Trial

(2008) Susan L. Greenspan et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Risedronate for the Prevention of Bone Loss in Premenopausal Women Undergoing Chemotherapy for Primary Breast Cancer

(2008) Stephanie L. Hines et al.   JOURNAL OF CLINICAL ONCOLOGY

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial

(2008)   LANCET ONCOLOGY

Compliance and persistence with osteoporosis therapies

(2008) Stuart L. Silverman et al.   Current Rheumatology Reports